HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

1,144.176

+37.8453.42%

Number of Gainers:16

Number of Losers:1

Number of Flat:1

PE:- -

High:1,148.964

Open:1,106.049

Low:1,097.950

Close:1,106.332

Volume:507.71M

Turnover:3.97B

Market Cap:771.53B

Float Cap:642.71B

Loading ...

CSPC Innovation Pharmaceutical posts RMB 241.13 million net loss in 2025 as revenue rises 8.93% to RMB 2.16 billion

BRIEF-Shanghai Junshi Biosciences Says As At Mar 16, Controlling Shareholder Increased A Shares By 365,382 Shares For Total RMB12.2 Mln

JUNSHI BIO Chairman Xiong Jun Increases Holdings by 365,400 A-Shares

CSPC PHARMA's Novel High-Selective PDE4B Inhibitor Receives Clinical Trial Approval in China

CSPC Pharmaceutical wins China clinical trial approval for SYH2059 inhalation therapy

CSPC Pharmaceutical - Syh2059 Powder for Inhalation Obtains FDA Clinical Trial Approval in U.S. in March 2026

THOMSON REUTERS

FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer

Clinical Trial Application for Baiyunshan's Xuhanting Granules in Pediatric Recurrent Respiratory Infections Receives Approval

Baiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing

Shandong Xinhua Pharmaceutical Receives Approval for Ezetimibe Tablet Holder Transfer

Fosun Pharmaceutical Gets Chinese Regulator's Nod for Clinical Trials of Blood Cancer Drug

MT Newswires Live

Alibaba Health Information Technology Stock Rallies 2.0% in Hong Kong

Sinopharm Group Stock Rallies 1.4% in Hong Kong

Sino Biopharmaceutical Stock Advances 2.4% in Hong Kong

JD Health International Stock Rises 5.0% in Hong Kong

CSPC Pharmaceutical Group Stock Climbs 5.1% in Hong Kong, Outperforms Competitors

BYD Electronic (International) Stock Climbs 3.0% in Hong Kong

Fengdong New District Releases Talent Demand Catalog for Key Industries

Sino Biopharmaceutical wins NMPA CDE consent to submit TQB3454 bile duct cancer marketing application

China's Basic Medical Insurance Coverage Exceeds 1.33 Billion in 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1515/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":1144.1763,"timestamp":1774598898612,"preClose":1106.3317,"halted":0,"volume":507708607,"delay":0,"changeRate":0.034207,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":37.844604,"latestTime":"03-27 16:00:00","open":1106.0487,"high":1148.9635,"low":1097.95,"amount":3972855764,"amplitude":0.046111,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"pbRate":2.080562,"peRate":22.562636,"turnoverRate":0.006709,"increases":16,"decrements":1,"flats":0,"marketCap":771527177856,"floatMarketCap":642714162176},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":1148.9635,"amplitude":0.046111,"preClose":1106.3317,"low":1097.95,"pbRate":"2.080562","latestPrice":1144.1763,"volume":507708607,"delay":0,"open":1106.0487,"prevYearClose":1190.107,"prevWeekClose":1138.752,"prevMonthClose":1247.044,"prevQuarterClose":1190.107,"fiveDayClose":1138.752,"twentyDayClose":1247.044,"sixtyDayClose":1208.526,"secType":"PLATE","market":"HK","turnoverRate":0.006709,"peRate":22.562636,"marketCap":771527177856,"floatMarketCap":642714162176,"timestamp":1774598898612,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":16,"down":1,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619465042","title":"CSPC Innovation Pharmaceutical posts RMB 241.13 million net loss in 2025 as revenue rises 8.93% to RMB 2.16 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2619465042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619465042?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:20","pubTimestamp":1773667235,"startTime":"0","endTime":"0","summary":"CSPC Innovation, a CSPC Pharmaceutical unit listed on the ChiNext Market of the Shenzhen Stock Exchange, reported 2025 operating revenue of RMB 2.16 billion, up 8.93%. CSPC Innovation posted a net loss attributable to shareholders of RMB 241.13 million in 2025, compared with net profit of RMB 53.73 million in 2024. Net cash flow from operating activities was negative RMB 195.69 million in 2025, improving 84.16% year over year. Total assets were RMB 6.28 billion at the end of 2025, and net assets attributable to shareholders were RMB 2.67 billion. CSPC Innovation said its annual report was published on the Shenzhen Stock Exchange website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the origina","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL30fXRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU0501845795.SGD","BK1515","LU0880133367.SGD","BK1521","LU1960683339.HKD","BK0226","LU1226288170.HKD","IE00B031HY20.USD","IE00B543WZ88.USD","LU0067412154.USD","LU1807302812.USD","LU0326950275.SGD","LU0314109678.HKD","IE00B5MMRT66.SGD","LU0072913022.USD","LU0140636845.USD","LU0315179316.USD","LU1152091168.USD","LU1152091754.HKD","300765","LU1226287529.USD","IE00BZ08YS42.EUR","01093","LU1951186391.HKD","BK1191","IE00BZ08YT58.USD","LU1813983027.USD","LU1008478684.HKD","IE00BZ08YR35.GBP","IE0008369823.USD","LU1328277881.USD","HK0000165453.HKD","SG9999004220.SGD","LU1993786604.SGD","LU1226287792.SGD","LU1226287875.USD","LU1226288253.USD","IE0008368742.USD"],"gpt_icon":0},{"id":"2619299463","title":"BRIEF-Shanghai Junshi Biosciences Says As At Mar 16, Controlling Shareholder Increased A Shares By 365,382 Shares For Total RMB12.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2619299463","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619299463?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:54","pubTimestamp":1773665661,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Says As At Mar 16, Controlling Shareholder Increased A Shares By 365,382 Shares For Total RMB12.2 MlnMarch 16  - Shanghai Junshi Biosciences Co Ltd 688180.SS:AS AT MAR 16, CONTROLLING SHAREHOLDER INCREASED SHAREHOLDINGS OF A SHARES BY 365,382 SHARES FOR TOTAL RMB12.2 MILLIONFurther company coverage: 688180.SS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN404076:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK0239","01877","BK1515","688180"],"gpt_icon":0},{"id":"1110990003","title":"JUNSHI BIO Chairman Xiong Jun Increases Holdings by 365,400 A-Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1110990003","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110990003?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:32","pubTimestamp":1773664356,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) announced that Mr. Xiong Jun, a controlling shareholder, one of the actual controllers, and Chairman of the Board of Shanghai Junshi Biosciences Co., Ltd., plans to increase his...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["399300","688180","BK1515","BK0239","01877","159982","BK1583","BK1161"],"gpt_icon":0},{"id":"1119051669","title":"CSPC PHARMA's Novel High-Selective PDE4B Inhibitor Receives Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1119051669","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119051669?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:54","pubTimestamp":1773658497,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) announced that its new chemical entity, a highly selective PDE4B inhibitor (SYH2059 inhalation powder), has received approval from China's National Medical Products Administration...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287529.USD","HK0000165453.HKD","LU0326950275.SGD","LU1960683339.HKD","BK1521","IE0008369823.USD","LU1807302812.USD","LU0067412154.USD","BK1515","LU1226288170.HKD","IE00BZ08YS42.EUR","LU0315179316.USD","LU1226287792.SGD","SG9999004220.SGD","BK1191","LU1993786604.SGD","LU0072913022.USD","LU0314109678.HKD","LU0140636845.USD","LU1328277881.USD","IE00B543WZ88.USD","LU1152091168.USD","LU0501845795.SGD","LU1951186391.HKD","IE0008368742.USD","LU1226288253.USD","LU0880133367.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1813983027.USD","LU2039709279.SGD","LU1008478684.HKD","IE00BZ08YT58.USD","LU1152091754.HKD","IE00BZ08YR35.GBP","01093"],"gpt_icon":0},{"id":"2619772454","title":"CSPC Pharmaceutical wins China clinical trial approval for SYH2059 inhalation therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2619772454","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619772454?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658246,"startTime":"0","endTime":"0","summary":"CSPC said China’s National Medical Products Administration has approved clinical trials for its SYH2059 powder for inhalation, a PDE4B inhibitor. The company said the U.S. FDA also cleared SYH2059 for clinical trials in the U.S. The approved indication in China is interstitial lung disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7CqGVw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1152091168.USD","LU1328277881.USD","01093","LU1960683339.HKD","IE00BZ08YS42.EUR","IE0008368742.USD","IE00B031HY20.USD","LU0880133367.SGD","LU1226288170.HKD","LU0315179316.USD","LU1008478684.HKD","LU0501845795.SGD","LU1152091754.HKD","BK1191","HK0000165453.HKD","LU1951186391.HKD","LU1226287529.USD","SG9999004220.SGD","BK1521","IE00B543WZ88.USD","LU0072913022.USD","BK1515","LU1226287792.SGD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","IE0008369823.USD","LU2039709279.SGD","LU0140636845.USD","LU1226287875.USD","LU0067412154.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","LU0314109678.HKD","IE00BZ08YT58.USD","LU1226288253.USD"],"gpt_icon":0},{"id":"2619454710","title":"CSPC Pharmaceutical - Syh2059 Powder for Inhalation Obtains FDA Clinical Trial Approval in U.S. in March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619454710?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658239,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040EF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999004220.SGD","LU1008478684.HKD","BK1191","IE00BZ08YS42.EUR","LU1152091754.HKD","LU1226287792.SGD","LU1226288253.USD","LU0072913022.USD","BK1521","IE0008368742.USD","LU1807302812.USD","01093","LU1960683339.HKD","IE00BZ08YR35.GBP","LU1993786604.SGD","LU0315179316.USD","IE00BZ08YT58.USD","IE00B543WZ88.USD","HK0000165453.HKD","LU0501845795.SGD","LU1813983027.USD","LU1226287529.USD","LU1226288170.HKD","LU1951186391.HKD","LU0314109678.HKD","IE0008369823.USD","LU1226287875.USD","LU0140636845.USD","LU1328277881.USD","LU0326950275.SGD","IE00B5MMRT66.SGD","LU0880133367.SGD","LU1152091168.USD","IE00B031HY20.USD","LU2039709279.SGD","LU0067412154.USD","BK1515"],"gpt_icon":0},{"id":"1188326337","title":"FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1188326337","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188326337?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658232,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries recently received approval from the National Medical Products Administration to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0188","BK0196","BK0187","BK0060","BK0096","BK0183","BK0028","BK1515","BK1593","600196","02196","BK0012","BK0239","BK1191"],"gpt_icon":0},{"id":"1120935628","title":"Clinical Trial Application for Baiyunshan's Xuhanting Granules in Pediatric Recurrent Respiratory Infections Receives Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1120935628","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120935628?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:35","pubTimestamp":1773657311,"startTime":"0","endTime":"0","summary":"Baiyunshan (00874) has announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK1606","BK1191","BK0239","BK0012","BK1515","BK0028","BK0070","BK0096","600332","BK0097","BK0175","BK0196","BK1197","00874","BK1521","BK0188"],"gpt_icon":0},{"id":"1187845305","title":"Baiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1187845305","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187845305?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:31","pubTimestamp":1773657074,"startTime":"0","endTime":"0","summary":"Baiyushan PH (00874) announced that on March 13, 2026, the company received a no-objection letter from the Shanghai Stock Exchange (SSE) forwarded by Industrial Securities Asset Management Co., Ltd....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0175","09939","BK1521","BK0097","BK0028","BK1574","BK1197","BK1515","159938","600332","BK1191","161027","BK0196","BK0070","BK1606","BK0096","00874","BK0239","BK1161","BK0012","BK0188"],"gpt_icon":0},{"id":"1122815816","title":"Shandong Xinhua Pharmaceutical Receives Approval for Ezetimibe Tablet Holder Transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=1122815816","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122815816?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:40","pubTimestamp":1773654034,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Limited announced that it recently received a Drug Supplement Application Approval Notice from the National Medical Products Administration for Ezetimibe...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","00719","BK1191"],"gpt_icon":0},{"id":"2619453250","title":"Fosun Pharmaceutical Gets Chinese Regulator's Nod for Clinical Trials of Blood Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453250","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619453250?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:39","pubTimestamp":1773650355,"startTime":"0","endTime":"0","summary":"China's drug regulator approved Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) clinical trials for its FXS0683 tablets, according to a Saturday filing with the Shanghai bourse.The drug is indicated for blood cancers, helps prevent tumor growth, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0012","BK0196","BK0187","BK0183","BK0239","BK0028","BK1191","BK0175","BK0096","BK1515","BK0188","02196","600196","BK1593"],"gpt_icon":0},{"id":"2619643453","title":"Alibaba Health Information Technology Stock Rallies 2.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2619643453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619643453?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:33","pubTimestamp":1773649980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Alibaba Health Information Technology Ltd. rose 2.0% to 5.12 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 25834.02.The stock's rise snapped a three-day losing streak.Alibaba Health Information Technology Ltd. closed 35% below its 52-week high of HK$7.91, which the company achieved Jan. 14.The stock outperformed some of its competitors, as HKT Trust & HKT Ltd. rose 0.7%.Trading volume totaled 74.8 million shares, compared to the 50-day average of 140.1 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0608807433.USD","LU1267930227.SGD","LU0164872284.USD","LU1323998911.USD","LU0127658192.USD","BK4554","LU0819121731.USD","IE0003895053.USD","LU1515016050.SGD","LU2039709279.SGD","LU0128522744.USD","LU0047713382.USD","LU0762541174.USD","LU1366334651.USD","LU0456846285.SGD","LU0577902371.SGD","LU1769817179.HKD","LU1720051017.SGD","IE00B0169N27.USD","LU1328277881.USD","BK1618","SGXZ62798434.SGD","SG9999001051.SGD","BK1588","IE0034224299.USD","LU1282648689.USD","LU0197773673.USD","BK1608","LU0819123356.HKD","SG9999001689.USD","SG9999001903.USD","LU0196878994.USD","BABW","BK4524","LU0449515922.USD","LU1224444064.USD","LU0315178854.USD","LU0823413660.USD","LU0594300179.USD","LU0165289439.USD","BK1517","BK1189","LU0577902538.SGD","LU1044876610.USD","LU0642271901.SGD","LU0011963245.USD","IE00BMPRXR70.SGD","LU0328353924.USD","LU0106259558.USD","LU0164865239.USD","SG9999006514.SGD","BK4533","LU0737861699.HKD","LU0608807946.USD","LU2087589342.USD","LU1813983027.USD","LU0043850808.USD","LU0737861772.HKD","LU0117844026.USD","LU0130518102.USD","HK0000306701.USD","LU0149534421.HKD","LU1008478684.HKD","LU0588545904.SGD","BK1249","BK4531","SGXZ90724238.SGD","IE00BZ08YR35.GBP","LU0132412106.USD","BK4535","LU1688375341.USD","BK1610","LU0345775950.USD","LU0762540952.USD","LU0823039010.USD","BK4526","BK4220","LU0531971595.HKD","LU0651946864.USD","LU0823397103.USD","LU1188198961.HKD","LU0072462343.USD","LU0823041008.USD","LU0862451753.SGD","LU0648000940.SGD","LU2125910849.SGD","LU0831103253.SGD","BK4538","BK1571","BBYY","LU0456842615.SGD","LU0048580855.USD","LU0561508036.HKD","LU0348783662.USD","BK1247","BK4585","LU0593848301.USD","LU1810669033.SGD","LU0634319403.HKD","LU1152091168.USD","LU0229945570.USD","LU1769817096.USD","SG9999002828.SGD","LU0211977185.USD","LU0117841782.USD","LU0130103400.USD","LU0345776255.USD","LU0821914370.USD","LU0235996351.USD","LU0417516571.SGD","LU0039217434.USD","LU1880383366.USD","LU0543330566.HKD","LU1048596156.SGD","BK4558","LU0865486749.SGD","SG9999000327.SGD","LU1880398554.USD","LU0417516738.SGD","LU0348805143.USD","BK1515","LU0048388663.USD","BK1617","LU0348735423.USD","LU0210527791.USD","IE00BFMHRM44.USD","LU0261947096.USD","LU0873338254.USD","LU0589944569.HKD","LU0501845795.SGD","LU0310800965.SGD","LU0327786744.USD","LU1003077747.HKD","LU0828237510.HKD","LU0348816934.USD","LU0307460666.USD","LU2476274308.USD","BK4575","LU0823413587.USD","BK4134","LU0545039389.USD","LU1152091754.HKD","LU0228659784.USD","LU0651947912.USD","LU0672654166.SGD","SG9999000459.SGD","LU0149721374.USD","LU1046422090.SGD","LU0516423174.USD","LU0499858602.USD","LU2449936058.SGD","89988","LU0051755006.USD","LU0540923850.HKD","LU1439103000.SGD","LU1568876251.USD","LU0516423091.SGD","LU0261950983.USD","LU0823426480.USD","LU1235294995.USD","HBBD.SI","LU2152927971.USD","LU0348814723.USD","SG9999002463.SGD","SG9999001226.SGD","LU0784639295.USD","LU0228367735.SGD","LU0463099449.HKD","LU0140636845.USD","LU0431992006.USD","LU0173614495.USD","LU0029875118.USD","LU0264606111.USD","LU0251143458.SGD","LU1282651121.HKD","LU0886674414.USD","LU0572940350.SGD","LU2476274720.SGD","LU2257852520.SGD","LU0231483743.USD","LU0348784397.USD","LU1548497426.USD","LU0572939691.SGD","LU0640798160.USD","BK1575","LU0254981946.USD","LU0244354667.USD","BK1615","LU0661504455.SGD","LU0143863198.USD","LU0856984785.SGD","LU1046421795.USD","LU0329678337.USD","LU0499858438.USD","LU0541502299.USD","LU0163747925.USD","LU0607220059.USD","BABO","LU2097828557.USD","LU0880133367.SGD","BK1586","LU1044875133.USD","LU3063872942.SGD","LU0052750758.USD","LU0516422366.SGD","BK1501","LU0762542818.HKD","LU0871576103.HKD","LU0169518387.USD","LU0359202008.SGD","LU0588545730.USD","LU0577902611.USD","BK4607","LU1282649141.HKD","LU0084288322.USD","LU1956131251.USD","BK4534","LU0348825331.USD","LU0469268626.HKD","LU2097828474.EUR","LU0823038988.USD","LU2357305700.SGD","LU0594300419.USD","LU1960683339.HKD","LU1823568750.SGD","LU0320764243.SGD","LU0823397285.USD","BK4505","LU0441854154.USD","LU0197773160.USD","BK1591","LU0477156797.USD","IE00B0JY6N72.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0210526637.USD","SG9999014674.SGD","LU0449509016.USD","LU0502904849.HKD","SG9999001093.SGD","LU0384037296.USD","LU1504937902.USD","LU0370786039.SGD","LU1642822792.SGD","LU0588545490.SGD","LU0359201612.USD","LU0828237940.HKD","BABU","IE00B3M56506.USD","LU0359201885.HKD","LU1770036033.HKD","LU0630378692.HKD","LU1719994722.HKD","IE0032431581.USD","LU1831875114.USD","LU0531970944.HKD","LU1808992512.USD","BK4579","LU1048588211.SGD","HK0000306685.HKD","LU0675040207.SGD","LU0164880469.USD","BK1584","SG9999002562.SGD","LU0543330483.HKD","LU0348827113.USD","IE0008368304.USD","LU0348788117.USD","IE00BF5LJ272.USD","LU0708995583.HKD","SG9999004220.SGD","IE00B543WZ88.USD","LU0456827905.SGD","LU0106959298.USD","LU1201861165.SGD","LU0048597586.USD","IE00BZ08YS42.EUR","LU0862451837.USD","LU0029874905.USD","BK4503","LU1282651048.USD","LU2148611432.USD","BK4504","LU1051769294.HKD","LU0541501648.USD","LU1770034418.SGD","LU0315179316.USD","BK1589","LU1328615791.USD","LU0918141887.USD","LU1481107354.HKD","LU2097829019.USD","LU1251922891.USD","LU0143863784.USD","LU0049853897.USD","LU0797268264.HKD","LU2125910500.SGD","LU1981816686.USD","LU1282649067.USD","00241","LU0320764599.SGD","BK4548","BK4588","HK0000320264.USD","LU1242518857.USD","LU1880398471.USD","BK4565","LU0708995153.HKD","LU0329678170.USD","LU2293587155.HKD","LU0630378429.USD","BABX","LU0251144936.SGD","LU0605514214.HKD","LU1868838027.USD","LU0326950275.SGD","HK0000320223.HKD","LU0348783233.USD","SGXZ86797644.SGD","LU1568876335.HKD","LU0648948544.HKD","LU0067412154.USD","LU0072913022.USD","LU0516422952.EUR","LU0949170772.SGD","LU1720051108.HKD","LU0577902298.EUR","LU2399975544.HKD","LU0577902454.USD","LU1316542783.SGD","LU2242644610.SGD","BK1142","LU0516422440.USD","LU0553294199.USD","LU2226246903.HKD","LU0293314216.USD","BK1521","LU1655091459.SGD","LU0572944931.SGD","LU0314109678.HKD","LU0588546209.SGD","LU0259732245.USD","LU1196710864.SGD","LU1282649810.SGD","BK4502","LU0831093199.SGD","LU0061477393.USD","LU0096374516.USD","LU0823040885.USD","LU1366334578.USD","LU2045819591.USD","LU1105468828.SGD","LU0128522157.USD","LU0890818403.SGD","LU1044874839.SGD","LU1224709979.USD","BK4587","LU0611395673.USD","LU0979878070.USD","IE00BMPRXN33.USD","LU0396098781.USD","LU0918141705.HKD","LU0455707207.USD","LU1880383440.USD","LU0320764755.SGD","LU1048484197.HKD","LU2097828805.USD","LU1993786604.SGD","LU0052756011.USD","LU0128525689.USD","BK4614","IE00B5MMRT66.SGD","LU1051768304.USD","LU1807302812.USD","LU0791590937.USD","LU1961090484.USD","LU0054450605.USD","LU1211504680.USD","BK4543","LU1720050803.USD","IE00BZ08YT58.USD","LU1242518931.SGD","LU0106252389.USD","LU0054237671.USD","BK4527","LU1303224171.USD","SG9999006597.SGD","LU0488056044.USD","LU1115378108.SGD","LU1794554557.SGD","LU0287142896.SGD","LU0868486357.SGD","LU2488822045.USD","LU2778985437.USD","LU0650527681.SGD","BK4122","BK1502","LU2097828631.EUR","LU2097828714.EUR","LU1023057109.AUD","KBAB","LU0791591158.USD","LU0181495838.USD","LU0700851271.USD","BK4581","LU0898667661.SGD","LU0738911758.USD","LU0823426308.USD","LU0214875030.USD","LU1868837565.USD"],"gpt_icon":0},{"id":"2619453679","title":"Sinopharm Group  Stock Rallies 1.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619453679?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:33","pubTimestamp":1773649980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. rallied 1.4% to 21.44 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 25834.02.This was the stock's third consecutive day of gains.Sinopharm Group Co. Ltd. closed 4.0% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 1.1%.Trading volume totaled 5.5 million shares, compared to the 50-day average of 5.4 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU1115378108.SGD","BK4175","01099","LU0640798160.USD","SHTDY","BK1500","BK1197"],"gpt_icon":0},{"id":"2619690453","title":"Sino Biopharmaceutical Stock Advances 2.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2619690453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619690453?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:31","pubTimestamp":1773649860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 2.4% to 6.09 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 25834.02.The stock's rise snapped a three-day losing streak.Sino Biopharmaceutical Ltd. closed 33% short of its 52-week high of HK$9.12, which the company achieved Sept. 10.The stock demonstrated a mixed performance when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 5.1% and Amgen Inc. remained unchanged.Trading volume totaled 45.6 million shares, compared to the 50-day average of 67.4 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","IE00BZ08YS42.EUR","BK1521","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1191","IE00BZ08YT58.USD","BK1589","01177"],"gpt_icon":0},{"id":"2619536504","title":"JD Health International Stock Rises 5.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2619536504","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619536504?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:31","pubTimestamp":1773649860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of JD Health International Inc. rose 5.0% to 51.45 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 25834.02.The stock's rise snapped a three-day losing streak.JD Health International Inc. closed 28% below its 52-week high of HK$71.70, which the company reached Jan. 15.Trading volume totaled 9.5 million shares, compared to the 50-day average of 8.1 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4509","IE0008368742.USD","BK4220","KJD","BK4614","LU0326950275.SGD","BK1583","BK4526","BK4551","LU0244354667.USD","BK1571","BK4579","SG9999002463.SGD","06618","LU1880383366.USD","BK4503","SGXZ86797644.SGD","IE00BGV7N243.SGD","BK1591","LU0463099449.HKD","LU1688375341.USD","HK0000306685.HKD","LU0456827905.SGD","BK4585","HK0000320264.USD","BK4558","BK4531","LU0051755006.USD","LU0106959298.USD","LU0307460666.USD","BK1247","BK1142","LU1188198961.HKD","HK0000306701.USD","BK4504","BK1515","86618","BK1589","BK4505","SGXZ62798434.SGD","BK1615","BK4524","LU0588546209.SGD","HK0000320223.HKD","BK4588","BK4122"],"gpt_icon":1},{"id":"2619536184","title":"CSPC Pharmaceutical Group Stock Climbs 5.1% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2619536184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619536184?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:31","pubTimestamp":1773649860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. advanced 5.1% to 9.03 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 25834.02.The stock's rise snapped a three-day losing streak.CSPC Pharmaceutical Group Ltd. closed 22% below its 52-week high of HK$11.63, which the company reached Sept. 9.The stock outperformed some of its competitors, as Sino Biopharmaceutical Ltd. rose 2.4%, SSY Group Ltd. rose 1.2%, and United Laboratories International Holdings Ltd. fell 1.7%.Trading volume totaled 87.1 million shares, compared to the 50-day average of 113.6 million shares.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072913022.USD","LU1008478684.HKD","LU1226287875.USD","IE00BZ08YR35.GBP","LU0315179316.USD","BK1521","IE00BZ08YT58.USD","LU0326950275.SGD","LU0880133367.SGD","LU1328277881.USD","LU1807302812.USD","BK1515","LU2039709279.SGD","LU1813983027.USD","01093","LU0067412154.USD","IE00B031HY20.USD","LU1951186391.HKD","IE00B543WZ88.USD","IE0008369823.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","LU1226287792.SGD","LU1226287529.USD","HK0000165453.HKD","IE0008368742.USD","LU1960683339.HKD","LU1152091754.HKD","SG9999004220.SGD","LU0314109678.HKD","LU1993786604.SGD","LU0501845795.SGD","IE00B5MMRT66.SGD","BK1191","LU1226288253.USD","LU0140636845.USD","LU1152091168.USD"],"gpt_icon":0},{"id":"2619453663","title":"BYD Electronic (International)  Stock Climbs 3.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619453663?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:31","pubTimestamp":1773649860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of BYD Electronic  Co. Ltd. rallied 3.0% to 31.10 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 25834.02.The stock's rise snapped a two-day losing streak.BYD Electronic  Co. Ltd. closed 41% below its 52-week high of HK$52.95, which the company achieved March 19.The stock outperformed some of its competitors, as Times Universal Group Holdings Ltd. remained unchanged.Trading volume totaled 8.2 million shares, compared to the 50-day average of 9.8 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1582","LU0348766576.USD","BK1589","00285","BK1515","LU0348767384.USD","BK1607","BK1149","LU0274383008.USD","BK1540","BK1580","BK1504"],"gpt_icon":0},{"id":"1142527956","title":"Fengdong New District Releases Talent Demand Catalog for Key Industries","url":"https://stock-news.laohu8.com/highlight/detail?id=1142527956","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142527956?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:21","pubTimestamp":1773642069,"startTime":"0","endTime":"0","summary":"The Fengdong New District in Xixian New Area has recently published the first batch of its 2026 Key Industrial Chain Talent Demand Catalog. The catalog includes 16 companies offering over 200 job...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09939","BK1161","BK1515"],"gpt_icon":0},{"id":"2619431671","title":"Sino Biopharmaceutical wins NMPA CDE consent to submit TQB3454 bile duct cancer marketing application","url":"https://stock-news.laohu8.com/highlight/detail?id=2619431671","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619431671?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:07","pubTimestamp":1773641236,"startTime":"0","endTime":"0","summary":"CTTQ Pharma, part of Sino Biopharm, said China’s drug regulator NMPA Center for Drug Evaluation has provided written consent to submit a marketing application for TQB3454 tablets for advanced IDH1-mutated bile duct cancer. The company said it plans to file the application in the near future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on March 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLbyzvDx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1515","BK1521","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1589","IE00BZ08YS42.EUR","BK1191","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"1101618720","title":"China's Basic Medical Insurance Coverage Exceeds 1.33 Billion in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1101618720","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101618720?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:02","pubTimestamp":1773640964,"startTime":"0","endTime":"0","summary":"According to a report released on the 16th via the National Healthcare Security Administration's official WeChat account, China's basic medical insurance system saw continued growth and optimization...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK1515","XLV","XBI","BK4585","09939","BK1161","BK4581","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":12,"totalSize":245,"code":"91000000","status":"200"}]}}